InvestSMART

Biome Australia Limited (ASX:BIO)

ALERT: Price-sensitive ASX Announcement for BIO
Current share price for BIO : $0.250 0.01 (4.17%)+
Announcement
Release
27 May 2026 8:43AM
Price at Release
$0.240
Full Release
download
Summary
Biome Australia Limited announced the commencement of a multi-centre BMB18 clinical trial across sites in Australia and Greece. The trial, initially a single-centre study, now includes Harokopio University of Athens as a second site alongside La Trobe University. This randomised, double-blind, placebo-controlled study will involve 240 participants over a six-week intervention and a two-week follow-up, assessing two dosages of BMB18. The trial aims to produce the first human clinical evidence for the Lactiplantibacillus plantarum strain, a proprietary development by Biome, which has filed a patent application. Recruitment is set to start this week in compliance with the established Q4 FY26 timeline.
Key Points
  • Multi-centre BMB18 clinical trial across Australia and Greece.
  • Inclusion of Harokopio University of Athens as a second site.
  • Randomised, double-blind, placebo-controlled study with 240 participants.
  • Assessment of two BMB18 dosages over six-week intervention.
  • Aims to produce first human clinical evidence for Lactiplantibacillus plantarum strain.
  • BMB18 is Biome's first wholly proprietary strain.
  • Recruitment commencing within Q4 FY26 timeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.